Medical Device Innovator, OxySure Systems, Reports 2nd Quarter Revenues up 54% over Comparable Quarter in 2014 - Video News Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2015) - Medical device innovator, OxySure Systems (OTCQB: OXYS), announced results for the latest quarter. For the three months ended June 30, 2015, revenues increased to $1,046,000, up 54% from the $678,000 reported in the second quarter of 2014, with gross profit also increasing by 54%, coming in at $637,000 versus $413,000 for the comparable period in 2014.

InvestmentPitch.com has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "OxySure" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_kt92qi52/Medical-device-innovator-OxySure-Systems-OTCQB-OXYS-announced-results-for-the-latest-quarter

The $0.04 net loss per share for the quarter was an improvement from the $0.05 net loss per share reported in the previous quarter ended March 31, 2015.

OxySure pioneered a ground-breaking technology to produce medically pure oxygen from inert powders, making the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen systems.

Subsequent to the second quarter, OxySure acted as an official Supplier of Medical Equipment for Health Services at the Special Olympics World Games held in Los Angeles from July 25th to August 2nd.

The OxySure Model 615 emergency oxygen device was deployed into all the competition venues and medical operations of the Games, along with Automated External Defibrillators (AEDs) and OxySure branded pulse oximeters.

During the Games, the OxySure Model 615 was instrumental in 18 potentially live saving situations.

In June, the company announced plans to add drones to carry kits designed for various types of emergencies or disasters, and filed with the Department of Transportation for exemption from the Federal Aviation Regulations for utilizing drones.

The payloads could include automated external defibrillators and accessories for cardiac arrest patients, as well as kits for victims of fire, flood, earthquake, chemical spill and a number of other emergency categories.

Julian T. Ross, Chairman and CEO of OxySure stated: "We are pleased with our results for the second quarter, and our momentum continues to build. We believe we are well positioned to achieve our goals for the remainder of the year. These include growing our sales force, solidifying our medical device platform, and uplisting our company to a national exchange."

Independent equity research firm SeeThruEquity has a price target of $2.30 on OxySure, calling the company "an intriguing speculative medical device company entering what should be a significant growth year, with an innovative product targeting a large potential market."

The shares are currently trading at $0.45.

For more information, please visit the company's website www.oxysure.com.

In Canada, investor relations is handled by Bettina Filippone of Renmark Financial Communications, who can be reached at bfilippone@renmarkfinancial.com.

In the US, please contact Jon Cunningham at Redchip Companies, who can be reached at jon@redchip.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com